Browse > Article
http://dx.doi.org/10.15429/jkomor.2018.18.1.1

Analysis of Adverse Events in Weight Loss Program in Combination with 'Gamitaeeumjowee-Tang' and Low-Calorie Diet  

Yoon, Na-Ra (Nubebe Korean Medical Clinic)
Yoo, Young-Jae (Nubebe Korean Medical Clinic)
Kim, Min-ji (Nubebe Korean Medical Clinic)
Kim, Seo-Young (Nubebe Korean Medical Clinic)
Lim, Young-Woo (Nubebe Korean Medical Clinic)
Lim, Hyung Ho (College of Korean Medicine, Gachon University)
Park, Young-Bae (Nubebe Mybou Research Institute)
Publication Information
Journal of Korean Medicine for Obesity Research / v.18, no.1, 2018 , pp. 1-9 More about this Journal
Abstract
Objectives: The objective of this study was to assess the safety of 'Gamitaeeumjowee-tang' by analyzing adverse events in weight loss program in combination with 'Gamitaeeumjowee-tang' and low-calorie diet. Methods: A retrospective review of adverse events in weight loss program in combination with 'Gamitaeeumjowee-tang' and low-calorie diet from the electronic medical chart (n=124) between June 2015 and December 2016 was conducted. Three Korean Medicine Doctors (KMDs) reviewed adverse events for two times, during week 2 to 4 and at week 10, after starting weight loss program. Adverse events were evaluated in terms of causality, severity and system-organ classes. Also, agreement among the three KMDs was made through further discussion in case of disagreement after independent review. Results: The overall rate of adverse events was 37.1% during week 2 to 4 and 16.9% at week 10. For causality of adverse events using the World Health Organization-Uppsala Monitoring Centre causality categories, 52.2% were evaluated 'possible' at week 2-4 and 57.1% were evaluated 'unlikely' at week 10. All symptoms were evaluated as 'mild' by LDS scale. Nausea (15, 12.1%) was the most frequent adverse event at week 2-4 and dizziness (6, 4.8%) was the most common at week 10. Conclusions: Adverse events decreased over time. There were no serious adverse events and none of the subjects were dropped due to adverse events. Continuous study is needed to prove the safety of 'Gamitaeeumjowee-tang' for treating obesity.
Keywords
Gamitaeeumjowee-tang; Adverse drug event; Safety; Weight loss program; Low-calorie diet;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Korean Society for the Study of Obesity. Clinical bariatrics. 3rd ed. Seoul : Korea Medical Book. 2008 : 143.
2 Ministry of Health and Welfare. Korea Centers for Disease Control and Prevention. Korea Health Statistics 2016: Korea National Health Statistics and Nutrition Examination Survey (KNHANESVII-1) [Internet]. Seoul(KR): KCDC; 2016 [cited 2018 Jan 4]. Available from: URL: https://knhanes.cdc.go.kr/knhanes/sub04/sub04_03.do?classType=7.
3 Korean Society for Health Promotion and Disease Prevention. Korean Society for Health Promotion and Disease Prevention 2012 spring academic conference. Seoul : Korean Society for Health Promotion and Disease Prevention. 2012 : 163-8.
4 Kim KK. Safety of anti-obesity drugs approved for long-term use. Korean J Obes. 2015 ; 24(1) : 17-27.   DOI
5 Jeong JW, Cho SW. Trend research of the human body-oriented obesity studies on Korean medicine. J Korean Med Rehab. 2016 ; 26(1) : 49-61.   DOI
6 Hwang MJ, Shin HD, Song MY. Literature review of herbal medicines on treatment of obesity since 2000; mainly about Ephedra Herba. J Korean Med Obes Res. 2007; 7(1) : 39-54.
7 Lee JM. Longevity and life preservation in Eastern medicine. 2nd. Seoul : Hanglimsa. 1993 : 19-24, 137-41.
8 Park KM, Song YK, Lim HH, Lee JA, Ko HY, Park JH, et al. Review on the research relative to Taeeumjowui-tang (Taiyintiaowei-tang). J Korean Med Obes Res. 2009 ; 9(1) : 23-36.
9 Lee JE, Song YK, Lim HH. Clinical trial of Taeeumjowui-tang (Taiyintiaowei-tang) on obese patients: randomized, double blind, placebo-controlled study. J Oriental Rehab Med. 2010 ; 20(4) : 197-213.
10 Park SJ, Won N, Cheon C, Park JS, Jang BH, Shin Y, et al. Efficacy and safety of taeeumjowi-tang in obese Korean adults: a double-blind, randomized, and placebo-controlled pilot trial. Evid Based Complement Alternat Med. 2013 ; 2013 : 498935. doi: 10.1155/2013/498935. Epub 2013 Aug 26.
11 Seo NJ, Nam DW, Lee EO, Sim BS, Ahn KS, Kim SH. Clinical study of Gamitaeeumjowi-tang for obese patients. Korean J Oriental Physiology & Pathology. 2008 ; 22(2) : 446-52.
12 Song MY, Kim HJ, Lee MJ. The safety guidelines for use of Ma-huang in obesity treatment. J Korean Med Obes Res. 2006; 6(2) : 17-27.
13 Korea Institute of Drug Safety & Risk Management. Adverse Drug Reaction Assessment Report. 1st ed. Seoul : Korea Institute of Drug Safety & Risk Management. 2013 : 60-3.
14 Korea Institute of Oriental Medicine. KMCPG-obesity. 1st ed. Seoul : Elsevier Korea. 2016 : 84-9.
15 Korean Society for the Study of Obesity. Clinical Practice Guidelines for Obesity 2012. 1st ed. Seoul : KOSSO. 2012 : 61-71.
16 World Health Organization-Uppsala Monitoring Centre (WHO-UMC). Causality categories [Internet]. Uppsala (Sweden): World Health Organization-Uppsala Monitoring Centre (WHO-UMC); 2018. [cited 2012 Oct 22]. Available from: https://who-umc.org/media/164200/who-umc-causality-assessment_new-logo.pdf.
17 Kim M, Han CH. Analysis of herbal-drug-associated adverse drug reactions using data from spontaneous reporting system in electronic medical records. J Korean Med. 2015 ; 36(1) : 45-60.   DOI
18 Kyung EJ, Ryu JH, Kim EY. Evaluation of adverse reactions to contrast media in the hospital. Br J Radiol. 2013 ; 86(1032) : 20130418.   DOI
19 Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1997 ; 277 : 301-6.   DOI
20 Korea Institute of Drug Safety & Risk Management. Terminology Guide for Reporting Adverse Drug Reactions. Seoul : Korea Institute of Drug Safety & Risk Management. 2014 : 1-6.
21 Chang MS, Shim KJ, Kim HY, Park EH, Ko EB, Choi BJ et al. Acute oral toxicity of Taeumjowi-tang in SD rats. Korean J Oriental Physiology & Pathology. 2008 ; 22(6) : 1439-43.
22 Jang IS, Yang CS, Hwang EH. The need for clinical practice guidelines in usage of Mahuang in weight loss. J Korean Med Obes Res. 2007 ; 7(1) : 23-9.
23 Jin YH, Kim KS, Han IY, Lee HB. Influence of prescribed Gamitaeeumjowi-tang on liver function: prospective single-center pilot study. J Korean Med Obes Res. 2010 ; 10(1) : 29-40.
24 Kim HJ, Kim JY. Clinical report about the adverse reactions of Taeeumin.Soeumin.Soyangin by Taeeumjowi-tang. Korean J Oriental Physiology & Pathology. 2008 ; 22(6) : 1600-5.
25 Jo GW, OK JM, Kim SY, Lim YW. Review on the efficacy and safety of Mahuang and ephedrine in the treatment of obesity-focused on RCT. J Korean Med. 2017 ; 38(3) : 170-84.   DOI
26 Shekelle PG, Hardy ML, Morton SC, Maglione M, Mojica WA, Suttorp MJ, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA. 2003 ; 289(12) : 1537-45.   DOI
27 Boozer CN, Daly PA, Homel P, Solomon JL, Blanchard D, Nasser JA, et al. Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. Int J Obes Relat Metab Disord. 2002 ; 26(5) : 593-604.   DOI
28 Greenway FL, Ryan DH, Bray GA, Rood JC, Tucker EW, Smith SR. Pharmaceutical cost savings of treating obesity with weight loss medications. Obes Res. 1999 ; 7(6) : 523-31.   DOI
29 Christensen P, Bliddal H, Riecke BF, Leeds AR, Astrup A, Christensen R. Comparison of a low-energy diet and a very low-energy diet in sedentary obese individuals: a pragmatic randomized controlled trial. Obes. 2011 ; 1(1) : 31-40.
30 Yancy WS Jr, Olsen MK, Guyton JR, Bakst RP, Westman EC. A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Ann Intern Med. 2004 ; 140(10): 769-77.   DOI